Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 34 studies | 32% ± 14% | |
endothelial cell of lymphatic vessel | 20 studies | 35% ± 14% | |
epithelial cell | 14 studies | 38% ± 17% | |
type I pneumocyte | 12 studies | 52% ± 20% | |
capillary endothelial cell | 12 studies | 29% ± 14% | |
endothelial cell of artery | 11 studies | 37% ± 14% | |
type II pneumocyte | 10 studies | 33% ± 15% | |
basal cell | 10 studies | 27% ± 11% | |
endothelial cell of vascular tree | 9 studies | 27% ± 7% | |
ciliated cell | 8 studies | 28% ± 14% | |
enterocyte | 7 studies | 27% ± 6% | |
secretory cell | 7 studies | 26% ± 14% | |
vein endothelial cell | 6 studies | 24% ± 6% | |
pericyte | 6 studies | 31% ± 19% | |
club cell | 6 studies | 30% ± 18% | |
mesothelial cell | 5 studies | 40% ± 10% | |
goblet cell | 5 studies | 21% ± 5% | |
abnormal cell | 4 studies | 25% ± 8% | |
keratinocyte | 4 studies | 29% ± 13% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 46% ± 18% | |
hepatocyte | 4 studies | 38% ± 17% | |
luminal cell of prostate epithelium | 4 studies | 29% ± 9% | |
extravillous trophoblast | 3 studies | 85% ± 8% | |
melanocyte | 3 studies | 20% ± 4% | |
oligodendrocyte | 3 studies | 18% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5983.67 | 459 / 459 | 99% | 231.64 | 1105 / 1118 |
liver | 100% | 22855.09 | 226 / 226 | 99% | 416.61 | 401 / 406 |
prostate | 99% | 7565.37 | 242 / 245 | 100% | 211.30 | 500 / 502 |
lung | 100% | 7997.76 | 578 / 578 | 98% | 239.53 | 1127 / 1155 |
thymus | 100% | 8057.22 | 652 / 653 | 97% | 139.12 | 589 / 605 |
pancreas | 96% | 2697.11 | 316 / 328 | 98% | 192.45 | 174 / 178 |
esophagus | 97% | 2778.20 | 1405 / 1445 | 97% | 133.71 | 177 / 183 |
stomach | 97% | 2751.79 | 350 / 359 | 94% | 140.46 | 269 / 286 |
kidney | 100% | 5688.31 | 89 / 89 | 90% | 152.71 | 815 / 901 |
uterus | 97% | 2443.79 | 165 / 170 | 93% | 210.11 | 428 / 459 |
intestine | 92% | 2713.28 | 886 / 966 | 98% | 163.19 | 515 / 527 |
bladder | 86% | 3573.33 | 18 / 21 | 94% | 174.33 | 474 / 504 |
ovary | 75% | 1344.23 | 135 / 180 | 97% | 107.47 | 419 / 430 |
brain | 69% | 1246.60 | 1829 / 2642 | 55% | 36.31 | 389 / 705 |
adrenal gland | 91% | 1927.81 | 235 / 258 | 32% | 26.90 | 74 / 230 |
skin | 72% | 7006.12 | 1304 / 1809 | 47% | 33.04 | 220 / 472 |
ureter | 0% | 0 | 0 / 0 | 100% | 155.92 | 1 / 1 |
adipose | 100% | 3645.05 | 1202 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 120.94 | 44 / 45 |
heart | 97% | 2289.27 | 835 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 50% | 874.02 | 666 / 1335 | 0% | 0 | 0 / 0 |
muscle | 43% | 666.03 | 344 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 40% | 22.43 | 32 / 80 |
spleen | 30% | 430.69 | 73 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 2% | 22.71 | 17 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061098 | Biological process | positive regulation of protein tyrosine kinase activity |
GO_0001525 | Biological process | angiogenesis |
GO_0048013 | Biological process | ephrin receptor signaling pathway |
GO_0043535 | Biological process | regulation of blood vessel endothelial cell migration |
GO_1903051 | Biological process | negative regulation of proteolysis involved in protein catabolic process |
GO_0003183 | Biological process | mitral valve morphogenesis |
GO_1902961 | Biological process | positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process |
GO_0061002 | Biological process | negative regulation of dendritic spine morphogenesis |
GO_0003180 | Biological process | aortic valve morphogenesis |
GO_0003199 | Biological process | endocardial cushion to mesenchymal transition involved in heart valve formation |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0007267 | Biological process | cell-cell signaling |
GO_0045765 | Biological process | regulation of angiogenesis |
GO_0050730 | Biological process | regulation of peptidyl-tyrosine phosphorylation |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0010719 | Biological process | negative regulation of epithelial to mesenchymal transition |
GO_0034446 | Biological process | substrate adhesion-dependent cell spreading |
GO_1902004 | Biological process | positive regulation of amyloid-beta formation |
GO_0014028 | Biological process | notochord formation |
GO_0033628 | Biological process | regulation of cell adhesion mediated by integrin |
GO_0050821 | Biological process | protein stabilization |
GO_0043409 | Biological process | negative regulation of MAPK cascade |
GO_0016477 | Biological process | cell migration |
GO_0007411 | Biological process | axon guidance |
GO_0050770 | Biological process | regulation of axonogenesis |
GO_0070244 | Biological process | negative regulation of thymocyte apoptotic process |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0098552 | Cellular component | side of membrane |
GO_0046875 | Molecular function | ephrin receptor binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | EFNA1 |
Protein name | Ephrin-A1 Ephrin-A1 (EPH-related receptor tyrosine kinase ligand 1) (LERK-1) (Immediate early response protein B61) (Tumor necrosis factor alpha-induced protein 4) (TNF alpha-induced protein 4) [Cleaved into: Ephrin-A1, secreted form] |
Synonyms | EPLG1 hCG_1745153 TNFAIP4 LERK1 |
Description | FUNCTION: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Plays an important role in angiogenesis and tumor neovascularization. The recruitment of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Exerts anti-oncogenic effects in tumor cells through activation and down-regulation of EPHA2. Activates EPHA2 by inducing tyrosine phosphorylation which leads to its internalization and degradation. Acts as a negative regulator in the tumorigenesis of gliomas by down-regulating EPHA2 and FAK. Can evoke collapse of embryonic neuronal growth cone and regulates dendritic spine morphogenesis. . FUNCTION: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Plays an important role in angiogenesis and tumor neovascularization. The recruitment of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Exerts anti-oncogenic effects in tumor cells through activation and down-regulation of EPHA2. Activates EPHA2 by inducing tyrosine phosphorylation which leads to its internalization and degradation. Acts as a negative regulator in the tumorigenesis of gliomas by down-regulating EPHA2 and FAK. Can evoke collapse of embryonic neuronal growth cone and regulates dendritic spine morphogenesis. . |
Accessions | P20827 A8K0M4 ENST00000368407.8 [P20827-1] ENST00000368406.2 [P20827-2] |